<DOC>
	<DOC>NCT00375492</DOC>
	<brief_summary>This trial is designed to compare the effects of twice-daily exenatide and twice-daily placebo on weight loss. This trial will evaluate overweight and obese subjects with type 2 diabetes who have inadequate glycemic control with metformin, sulfonylurea, or metformin plus a sulfonylurea. Subjects will be treated with exenatide or placebo in addition to their current oral antidiabetes agent regimen and participate in a lifestyle modification program.</brief_summary>
	<brief_title>Effect on Weight Loss of Exenatide Versus Placebo</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Diagnosed with type 2 diabetes for at least 6 months Have been treated with a stable dose of the following for at least 6 weeks prior to screening: *immediate or extended release metformin, or *a sulfonylurea, or *a fixeddose sulfonylurea/metformin combination therapy Have an HbA1c of 6.6% to 10.0%, inclusive Have a Body Mass Index (BMI) of 25 kg/m^2 to 39.9 kg/m^2, inclusive Are treated with any of the following excluded medications: *exogenous insulin, thiazolidinedione, or alphaglucosidase inhibitor for more than 1 week within 6 weeks of screening; *Symlin injection at any time; * Byetta injection within 3 months of screening or discontinuation of therapy at any time due to adverse reaction; *drugs that directly affect gastrointestinal motility; *use of a weight loss drug (including those available over the counter) within 3 months of screening; *chronic (lasting longer than 2 weeks) systemic corticosteroids (excluding topical, intranasal, and inhaled preparations) by oral, intravenous, or intramuscular route within 2 months of screening Have conditions contraindicating metformin and/or sulfonylurea use Have had a change in lipidlowering agents within 6 weeks of screening Have received glucagonlike peptide1 (GLP1) analogs, or dipeptidyl peptidaseIV inhibitors (DPPIV inhibitors) or have previously participated in this study Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>overweight</keyword>
	<keyword>obesity</keyword>
	<keyword>weight loss</keyword>
	<keyword>exenatide</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>